Palabras clave
Nefropatía de células falciformes
Angiopoyetina-2
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Demostrar, a través de la literatura científica existente, la participación de la angiopoyetina-2 en el desarrollo de la nefropatía falciforme. Revisión de la literatura: La anemia de células falciformes (SCA) es una hemoglobinopatía hereditaria caracterizada por la homocigosidad de la hemoglobina S (HbS) y se asocia con complicaciones vasculares e inflamatorias que pueden afectar múltiples órganos, incluidos los riñones. El desarrollo de la nefropatía de células falciformes (NF) en pacientes con SCA es multifactorial e involucra mecanismos como hemólisis intravascular, eventos vasooclusivos, lesiones por isquemia-reperfusión, disfunción endotelial y estado proangiogénico. La angiopoyetina-2 (Ang-2) actúa en la angiogénesis y ha sido descrita como un biomarcador de disfunción endotelial y en la progresión de la nefropatía en diferentes etiologías, estando involucrada en la regulación de la permeabilidad vascular y en la activación del proceso inflamatorio. Consideraciones finales: En el contexto de la FA, la hipoxia resultante de eventos de vasooclusión y hemólisis intravascular induce la liberación de factores proangiogénicos, como Ang-2, agravando la lesión renal a través del aumento de la permeabilidad vascular. Además, se están desarrollando varios estudios que involucran a Ang-2 como objetivo terapéutico en enfermedades que cursan con angiogénesis anormal. Abriendo el camino para un posible manejo terapéutico de las complicaciones causadas por el estado proangiogénico en pacientes con FA, incluida la NF.
Referencias
ADEBAYO OC, et al. Sickle cell nephropathy: insights into the pediatric population. Pediatric Nephrology, 2022; 37(6): 1231-1243.
AKWII RG, et al. Role of angiopoietin-2 in vascular physiology and pathophysiology. Cells, 2019; 8(5): 471.
ANDRAWES NG, et al. Angiopoietin-2 as a marker of retinopathy in children and adolescents with sickle cell disease: relation to subclinical atherosclerosis. Journal of Pediatric Hematology/Oncology, 2019; 41(5): 361-370.
ANTWI-BOASIAKO C, et al. Elevated proangiogenic markers are associated with vascular complications within Ghanaian sickle cell disease patients. Medical Sciences, 2018; 6(3): 53.
ATAGA KI, et al. The nephropathy of sickle cell trait and sickle cell disease. Nature Reviews Nephrology, 2022; 18(6): 361-377.
AYGUN B, et al. Glomerular hyperfiltration and albuminuria in children with sickle cell anemia. Pediatric Nephrology, 2011; 26: 1285-1290.
BOZZA MT e JENEY V. Pro-inflammatory actions of heme and other hemoglobin-derived DAMPs. Frontiers in Immunology, 2020; 11: 1323.
BRANDOW AM e LIEM RI. Advances in the diagnosis and treatment of sickle cell disease. Journal of Hematology & Oncology, 2022; 15(1): 20.
CHANG F, et al. Angiopoietin-2 is associated with albuminuria and microinflammation in chronic kidney disease. PloS One, 2013; 8(3): e54668.
CHEN G, et al. Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood, 2014; 123(24): 3818-3827.
CHIMUCO KSM. A doença falciforme como factor protector contra a Malária. Revista Angolana de Ciências da Saúde/Angolan Journal Of Health Sciences, 2022; 3(2): 4-9.
CONGER AK, et al. Hemoglobin increases leukocyte adhesion and initiates lung microvascular endothelial activation via Toll-like receptor 4 signaling. American Journal of Physiology-Cell Physiology, 2023 ; 324(3): C665-C673.
DAVID S, et al. Circulating angiopoietin-2 levels increase with progress of chronic kidney disease. Nephrology Dialysis Transplantation, 2010; 25(8): 2571-2579.
DUITS AJ, et al. Serum levels of angiogenic factors indicate a pro‐angiogenic state in adults with sickle cell disease. British Journal of Haematology, 2006; 134(1): 116-119.
ESHBACH ML, et al. Hemoglobin inhibits albumin uptake by proximal tubule cells: implications for sickle cell disease. American Journal of Physiology-Cell Physiology, 2017; 312(6): C733-C740.
ESOH K e WONKAM A. Evolutionary history of sickle-cell mutation: implications for global genetic medicine. Human Molecular Genetics, 2021; 30(R1): R119-R128.
FALLAH A, et al. Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases. Biomedicine & Pharmacotherapy, 2019; 110: 775-785.
FERRO DESIDERI L, et al. Faricimab for the treatment of diabetic macular edema and neovascular age-related macular degeneration. Pharmaceutics, 2023; 15(5): 1413.
GILLEN J, et al. Angiopoietin-1 and angiopoietin-2 inhibitors: clinical development. Current Oncology Reports, 2019; 21: 1-7.
HAN J, et al. Voxelotor and albuminuria in adults with sickle cell anemia. British Journal of Haematology, 2022; 197(5): e63.
HEBBEL RP, et al. The multifaceted role of ischemia/reperfusion in sickle cell anemia. The Journal of Clinical Investigation, 2020; 130(3): 1062-1072.
HILBERT T, et al. Endothelial permeability following coronary artery bypass grafting: an observational study on the possible role of angiopoietin imbalance. Critical Care, 2016; 20(1): 1-13.
ITO MT, et al. Angiogenesis‐related genes in endothelial progenitor cells may be involved in sickle cell stroke. Journal of the American Heart Association, 2020; 9(3): e014143.
KATO GJ, et al. Intravascular hemolysis and the pathophysiology of sickle cell disease. The Journal of Clinical Investigation, 2017; 127(3): 750-760.
LI M, et al. Impact of angiopoietin-2 on kidney diseases. Kidney Diseases, 2023; 9(3): 143-156.
LIMA LC, et al. Fisiopatologia da doença renal crônica em adultos com doença falciforme. Revista Hospital Universitário Pedro Ernesto, 2015; 14(3).
LOPES FC, et al. Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea. Haematologica, 2015; 100(6): 730.
LUO A, et al. Exploring angiopoietin-2: Clinical insights and experimental perspectives in kidney diseases. Kidney International Reports, 2024.
MAHMUD S, et al. Hemoglobin cast nephropathy. Kidney International Reports, 2020; 5(9): 1581-1585.
NASCIMENTO AF, et al. Retinopatia em pacientes com doença falciforme: uma revisão de literatura. Research, Society and Development, 2020; 9(10): e2839108602.
PAVITRA E, et al. Impacts of oxidative stress and anti-oxidants on the development, pathogenesis, and therapy of sickle cell disease: A comprehensive review. Biomedicine & Pharmacotherapy, 2024; 176: 116849.
PAYÁN-PERNÍA S, et al. Nefropatía falciforme. Manifestaciones clínicas y nuevos mecanismos implicados en el daño renal. Nefrologia, 2021; 41(4): 373-382.
PICCIN A, et al. Insight into the complex pathophysiology of sickle cell anaemia and possible treatment. European Journal of Haematology, 2019; 102(4): 319-330.
PIEL FB, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet, 2013; 381: 142-151.
SUNDD P, et al. Pathophysiology of sickle cell disease. Annual Review of Pathology: Mechanisms of Disease, 2019; 14(1): 263-292.
SZYMCZAK A, et al. High plasma angiopoietin-2 levels predict the need to initiate dialysis within two years in patients with chronic kidney disease. International Journal of Molecular Sciences, 2023; 24(12): 10036.
TEIXEIRA RS e LADEIA AM. Disfunção endotelial na anemia falciforme: uma agressão vascular pela ativação do endotélio. Anemia Falciforme e Comorbidades Associadas na Infância e na Adolescência, 2020; 4.
TSAI YC, et al. Association of angiopoietin-2 with renal outcome in chronic kidney disease. PloS One, 2014; 9(10): e108862.
VALLELIAN F, et al. Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics. Blood, 2022; 140(17): 1837-1844.
ZHANG J, et al. Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: A meta-analysis and systematic review. Expert Review of Anticancer Therapy, 2024; 24(9): 881-891.